From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals ...

Penile nerve blocks, local anesthetics, various operative instruments, acetaminophen, sweet oral solutions ... circumcision pain (Fig 1). Mix 15 g of table sugar in 60 mL of sterile water to ...

Omeprazole in oral suspension was safe and effective in pediatric clinical trials conducted in infants aged 1-24 months ... or suspended in 5 mL of water and given via oral syringe.

The anti-ulcer activities were also evaluated, showing that oral administration ... were dissolved in 0.5 gm/100 ml of deionized water. 2.3.3. For Carbohydrates A hyopercarb column, 5U 100 × 4.6 mm in ...

LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at any time of the day without restrictions on food and water intake.

Eli Lilly adds that Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial.

NEW YORK, April 14, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1 ...

The Clay County Prosecutor’s Office released new details Monday afternoon about two “major” drug arrests that took place over ...

Pfizer said it would end development of its oral GLP-1 receptor agonist danuglipron for weight loss due to a potential case of drug-induced liver injury. After the Trump administration opted not ...

The SOUL (NCT03914326) clinical trial is the first to assess the cardiovascular benefits of an oral GLP-1 inhibitor, building on its effectiveness aligns with injectable formulations.

The once-daily oral GLP-1 receptor agonist significantly reduced blood sugar and body weight in adults with Type 2 diabetes and had a safety profile consistent with injectable therapies ...